With fresh data, a dynamic duo powers Eli Lilly to new heights

EliLillyCEODavidRicks(left)andChiefScientificOfficerDanielS.SkovronskyMollyFergusonforSTATThepartner WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.




explore

author：entertainment    Page View：3327
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Gene therapy has helped boys walk. Can scientists keep it that way?
Next article： Peter Hotez and the public health issue of online harassment